Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open Label, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies

Trial Profile

A Phase 1, Open Label, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Medarex
  • Most Recent Events

    • 28 Jan 2023 Results assessing safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates published in the Journal of Clinical Oncology
    • 22 May 2019 Results of Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients using data from 2 predominantly Chinese and 5 global studies, published in the Journal of Clinical Pharmacology
    • 15 May 2019 Results of PPK analysis using data from multiple clinical studies in patients with AdjMEL, MEL, NSCLC, and other tumor types (CA209-001, CA209-003, CA209-005, CA209-017, CA209-057, CA209-037, CA209-066, CA209-238, CA209-063 and CA209-051) published in the Clinical Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top